← Back
NeuroTrials.ai
Neurology Clinical Trial Database

RINOMAX

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial

Year of Publication: 2022

Authors: Fredrik Piehl, Ann Eriksson-Dufva, Anna Budzianowska, ..., Thomas Frisell

Journal: JAMA Neurology

Citation: JAMA Neurol. 2022;79(11):1105-1112

Link: https://doi.org/10.1001/jamaneurol.2022.2887


Clinical Question

Is a single low-dose infusion of rituximab (500 mg) associated with greater probability of achieving minimal disease manifestations at 4 months in patients with recent-onset generalized myasthenia gravis compared to placebo?

Bottom Line

A single 500 mg infusion of rituximab significantly increased the proportion of patients achieving minimal disease manifestations (71% vs 29%) at 16 weeks and substantially reduced the need for rescue therapies (4% vs 36%), supporting early rituximab use in new-onset generalized MG.

Major Points

  • Primary endpoint achieved: 71% (17/24) with rituximab vs 29% (6/21) with placebo met minimal disease manifestations at 16 weeks (PR 2.48, P = .007)
  • Rituximab dramatically reduced need for rescue treatment: 4% vs 36% (P = .008)
  • No hospitalizations for MG exacerbation in rituximab group vs 3 in placebo group (including 1 requiring mechanical ventilation)
  • Secondary endpoints showed no difference with per-protocol analysis due to differential censoring, but post hoc worst rank analysis favored rituximab
  • Low-dose single infusion protocol (500 mg) was used, similar to Swedish MS protocols
  • All but 2 patients were AChR+; the 2 seronegative patients were MuSK-
  • One fatal cardiac event occurred in rituximab arm in patient with preexisting ischemic heart disease
  • One patient randomized to rituximab was later diagnosed with ALS (initial MG diagnosis was incorrect)

Design

Study Type: Randomized, double-blind, placebo-controlled, parallel-group trial

Randomization: 1

Blinding: Double-blind: patients, investigators, and all study personnel were blinded. Central pharmacy prepared and shipped blinded study drug in identical containers

Enrollment Period: October 20, 2016 to March 2, 2020

Follow-up Duration: 48 weeks

Centers: 7

Countries: Sweden

Sample Size: 47

Analysis: Intention-to-treat for primary endpoint using Fisher exact test. Secondary endpoints analyzed with Mann-Whitney U tests among those without rescue treatment (per-protocol) with Bonferroni-adjusted alpha = 0.0167. Probability ratios estimated with log-binomial regression with robust standard errors. Post hoc worst rank imputation for rescue treatment. SAS version 9.4.


Inclusion Criteria

  • Age >=18 years
  • Onset of generalized MG symptoms <=12 months prior to inclusion (no time limit for isolated ocular symptoms)
  • QMG score >=6 (measured >=12 hours after last AChEI dose)
  • MGFA classification II-IV
  • MG diagnosis confirmed by at least 2 of: positive AChR antibody test, abnormal electrophysiology (RNS or SFEMG), or clinically significant AChEI response

Exclusion Criteria

  • MGFA classification I or V at screening
  • Prior thymectomy or suspected thymoma on radiology
  • Significant comorbidity
  • Use of immunosuppressive therapy (rituximab, azathioprine, ciclosporin, mycophenolate) within 12 months
  • Pulsed high-dose corticosteroids within 12 months
  • Prednisolone >40 mg/d or treatment >3 months was not exclusionary
  • IVIg or plasma exchange within 12 months was not exclusionary

Arms

FieldControlRituximab 500 mg
InterventionMatching placebo intravenous infusion, single dose at baseline. Premedication with paracetamol 1000 mg, cetirizine 10 mg, and prednisone 50 mgSingle intravenous infusion of 500 mg rituximab at baseline. Premedication with paracetamol 1000 mg, cetirizine 10 mg, and prednisone 50 mg
DurationSingle infusion with 48-week follow-upSingle infusion with 48-week follow-up

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Minimal disease manifestations at week 16 defined as QMG score <=4, daily prednisolone dose <=10 mg, and no rescue treatment during weeks 9-16Primary6/21 (29%)17/24 (71%)42.26%.007
Change in QMG score from baseline to week 24 (per-protocol, censored for rescue)Secondary-5.8 (4.6)-6.9 (5.6).79
Change in MG-ADL score from baseline to week 16 (per-protocol)Secondary-0.5 (3.6)-1.7 (2.5).34
Change in MG-QoL score from baseline to week 16 (per-protocol)Secondary-7.0 (9.3)-9.2 (9.2).47
Minimal disease manifestations at week 24 (tertiary)Secondary8/21 (38%)18/25 (72%)PR 1.89 (95% CI 1.04-3.44).036
Patients receiving any rescue therapy before 24 weeksSecondary8/22 (36%)1/25 (4%)PR 0.11 (95% CI 0.01-0.81).008
Change in QMG score week 24 (post hoc, worst rank imputation)Secondary-2.0 (6.0)-6.5 (5.9).04
Change in MG-ADL score week 16 (post hoc, worst rank imputation)Secondary2.0 (5.0)-1.3 (3.2).03
Change in MG-QoL score week 16 (post hoc, worst rank imputation)Secondary-2.1 (11.1)-8.4 (10.2).06
Hospitalization due to MG exacerbationSecondary30
AChR antibody titer at week 24 - nmol/LSecondary77.1 (159.0)12.5 (21.0).16
Total adverse eventsAdverse4481
Patients with >=1 adverse eventAdverse18 (82%)21 (84%)
Infusion reactions (all mild)Adverse1 (5%)3 (12%)
Severe adverse eventsAdverse4 (18%)6 (24%)
Patients with >=1 severe adverse eventAdverse3 (17%)5 (20%)
Fatal severe adverse eventAdverse01 (4%)
Life threatening eventsAdverse2 (9%)0
Upper respiratory tract infectionsAdverse8 (36%)7 (28%)
Bacterial infections requiring systemic antibioticsAdverse2 (9%)3 (14%)
Musculoskeletal painAdverse5 (23%)8 (32%)
DiarrheaAdverse2 (9%)6 (24%)
NauseaAdverse1 (5%)4 (16%)
RashAdverse3 (12%)3 (14%)

Subgroup Analysis

Sensitivity analyses adjusting for age, early-onset disease, and MGFA classification showed crude OR 6.07 (95% CI 1.67-22.1) and adjusted OR 4.63 (95% CI 1.08-19.8), both significant. Post hoc analysis excluding patients younger than 40 years and those with severe comorbidity yielded virtually unchanged results. Late-onset MG (92% of rituximab arm) typically has more severe disease with less chance of spontaneous remission compared to early-onset MG.


Criticisms

  • Small sample size (n=47) limits generalizability and statistical power
  • Baseline imbalances between groups: placebo group was younger, had higher AChR titers, lower proportion on prednisolone, and more MGFA class III disease
  • Randomization was done without stratification, contributing to baseline imbalances
  • Secondary endpoints failed to show significance due to differential censoring from rescue treatment (disproportionately affected placebo arm)
  • One participant in rituximab arm was later diagnosed with ALS (misdiagnosed as MG initially)
  • One thymoma was discovered post-enrollment in placebo arm despite exclusion criteria
  • Low-dose rituximab protocol (500 mg) may not be optimal; higher doses might show greater efficacy
  • Long-term benefit-risk balance not established from this 48-week study
  • Predominantly late-onset MG population (92% in rituximab arm) limits applicability to early-onset MG
  • Only 2 MuSK+ patients enrolled, preventing subgroup analysis for this population
  • Fatal cardiac event in rituximab arm occurred in patient with preexisting ischemic heart disease

Funding

Swedish Medical Research Council (grants 2015-00887 and 2020-02700)

Based on: RINOMAX (JAMA Neurology, 2022)

Authors: Fredrik Piehl, Ann Eriksson-Dufva, Anna Budzianowska, ..., Thomas Frisell

Citation: JAMA Neurol. 2022;79(11):1105-1112

Content summarized and formatted by NeuroTrials.ai.